Abstract: The present disclosure provides compounds and the preparation methods, lipid nanoparticles, and pharmaceutical compositions thereof. The compound includes at least one structural formula (I-1) and may be provided as a pharmaceutically acceptable salt, prodrug, or isomer. The compounds of the present disclosure increase structural diversity among lipid molecules. The structure of the compounds directly provides biodegradablity. The L1a, L1b, and L1c groups in the compounds can be interchanged with the L2 group, enabling the integration of other molecules such as steroids and peptides for direct and fast screening. This interchangeability expands the functionality of the cationic lipid compounds, allowing for the direct coupling of functional molecules to the lipid compound to expand its functions. The replaceable L groups offer greater flexibility in selecting L1a, L1b, L1c, and L2.

Abstract: The disclosure provides a branched structure polypeptide peptide carrier and its variations. The branched structure peptide has the following sequence formula: The technical solution of the disclosure enables efficient delivery of nucleic acids to tissues and organs in vivo for targeted therapy. The polypeptides have several times more conformational flexibility and affinity than macromolecular drugs (proteins and antibodies). The branched structure polypeptides possess long-lasting in vivo stability while maintaining strong affinity and minimal toxicity. By forming stable nanocomplexes or nanoparticles through electrostatic interactions with nucleic acid molecules, they can facilitate the delivery of nucleic acid drugs and their stable release inside cells, thereby enhancing the activity of nucleic acid-based therapeutics.

Abstract: Disclosed are an automatic scoring method and an automatic scoring system for abdominal aortic calcification to simulate the doctor's scoring process. The CNN is first used to locate and recognize the aorta from the first lumbar vertebra to the fourth lumbar vertebra and the aorta in the corresponding area, then an improved regression model is used to automatically perform the scoring task. With particular attention to the continuity of sample data, a regression model that can capture the continuity of the intrinsic ordered relationship between samples is designed to ensure that the changing trend of the calcification degree is reflected more accurately. A regression model is constructed based on the intrinsic continuity of samples, which solves the problem of ignoring data continuity in the direct regression method, making the scoring to be more reflective of the continuous changes in calcification severity.

Abstract: The invention provides compositions containing a stable crystalline form of brequinar and methods of making such composition. The invention also provides methods of using such compositions to treat a condition in a subject.

Abstract: The present invention relates to a novel cyclic peptide carrier in the field of pharmaceutical technology and its various forms, where the cyclic peptide has the general sequence formula P-(X)m-Cys-(Y)n-Cys-(Z)o-P. The invention also encompasses the construction and preparation technology of a composition or formulation formed by the novel cyclic peptide carrier carrying nucleic acids, drugs, or therapeutic agents. Furthermore, it involves a method for effectively delivering nucleic acids to cells, tissues, or organisms using the composition or formulation, as well as its medical applications.

Abstract: The invention provides compositions containing a stable crystalline form of brequinar and methods of making such composition. The invention also provides methods of using such compositions to treat a condition in a subject.

Abstract: A salt serving as an Akt inhibitor and a crystal thereof, specifically related to a salt of the compound of formula (I) and a crystal thereof.

Abstract: The invention provides compositions containing a stable crystalline form of brequinar and methods of making such composition. The invention also provides methods of using such compositions to treat a condition in a subject.

Abstract: The invention provides compositions containing a stable crystalline form of brequinar and methods of making such composition. The invention also provides methods of using such compositions to treat a condition in a subject.

Abstract: The present invention discloses to a hydrochloride salt, a citrate salt, a phosphate salt or a sulfate salt of compound 1, the crystal forms of the aforementioned salts, and a preparation method thereof. The present invention also relates their use in the preparation of a medicament for the treatment of cerebral apoplexy or epilepsy.

Abstract: A salt serving as an Akt inhibitor and a crystal thereof, specifically related to a salt of the compound of formula (I) and a crystal thereof.

Abstract: The present invention discloses a crystal form and salt of a nitroimidazole compound, and a manufacturing method thereof. The invention further comprises an application of the crystal form and salt in preparing a pharmaceutical product for preventing and treating an infection caused by Mycobacterium tuberculosis or another microbe.

Abstract: The present invention discloses to a hydrochloride salt, a citrate salt, a phosphate salt or a sulfate salt of compound 1, the crystal forms of the aforementioned salts, and a preparation method thereof. The present invention also relates their use in the preparation of a medicament for the treatment of cerebral apoplexy or epilepsy.